Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T

Executive Summary

Yescarta is off to a strong launch, but with US FDA approval of Novartis' Kymriah in a similar indication it now it has a competing CAR-T product with a similar label. Gilead's HCV business declined as expected, but the HIV franchise had a worse Q1 than anticipated. 

Advertisement

Related Content

Gilead’s Yescarta Growth Continues, But Momentum Slowed
Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
EU CAR-T Race Tightens After Yescarta Reverts To Standard Review
Gilead's R&D Leadership Change Is End Of Bischofberger Era
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Gilead Completes HCV Clinical Development With Vosevi Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123013

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel